Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)

Multiple Cancer Types

The primary objective of this study now is to assess the anti-neoplastic activity of flotetuzumab in patients with PIF / ER AML, as determined by the proportion of patients who achieve complete remission (CR) or complete remission with partial hematologic recovery (CRh).
Leukemia, Myelodysplastic Syndrome, Phase I
I/II
Byrne, Michael
NCT02152956
VICCHEMP1828

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: